Epithelial-to-mesenchymal transition (EMT) is a critical event in the progression toward cancer metastasis. The intermediate filament protein vimentin is an important marker of EMT and a requisite regulator of mesenchymal cell migration. However, it is not known how vimentin functionally contributes to cancer cell invasion. Here, we report that ectopic expression of oncogenic H-Ras-V12G and Slug induces vimentin expression and migration in pre-malignant breast epithelial cells. Conversely, vimentin expression is necessary for Slug-or H-Ras-V12G-induced EMT-associated migration. Furthermore, silencing of vimentin in breast epithelial cells results in specific changes in invasiveness-related gene expression including upregulation of RAB25 (small GTPase Rab25) and downregulation of AXL (receptor tyrosine kinase Axl), PLAU (plasminogen activator, urokinase) and ITGB4 (integrin b4-subunit). Importantly, gene expression profiling analyses reveal that vimentin expression correlates positively/ negatively with these genes also in multiple breast cancer cell lines and breast cancer patient samples. Focusing on the tyrosine kinase Axl, we show that induction of vimentin by EMT is associated with upregulation of Axl expression and that Axl enhances the migratory activity of pre-malignant breast epithelial cells. Using null and knock-down cells and overexpression models, we also show that regulation of breast cancer cell migration in two-and three-dimensional matrices by vimentin is Axldependent and that Axl functionally contributes to lung extravasation of breast cancer cells in mice. In conclusion, our data show that vimentin functionally contributes to EMT and is required for induction of Axl expression. Moreover, these results provide a molecular explanation for vimentin-dependent cancer cell migration during EMT by identifying Axl as a key proximal component in this process.
Introduction
Epithelial-to-mesenchymal transition (EMT) is a unique process in which epithelial cells lose their cell-cell contacts and apical-basal polarity, and transdifferentiate into fibroblastic migratory cells with mesenchymal characteristics. It has been proposed that EMT is involved in cancer progression, particularly during invasion and intravasation when tumor cells migrate to distant organs to form metastases (Thiery, 2002; Gupta and Massague, 2006) .
Intermediate filaments are a family of proteins that form one of the tripartite components of the cytoskeleton. They are expressed in a highly regulated manner in terms of tissue and developmental stage specificity and have important functions in human health and disease (Toivola et al., 2005) . Vimentin is an intermediate filament protein normally expressed in cells of mesenchymal origin (Steinert and Roop, 1988) . However, vimentin can also be expressed in epithelial cells undergoing EMT both under physiological and pathological situations (Franke et al., 1982; Thiery, 2002; Gupta and Massague, 2006) .
Vimentin regulates cell migration in many cell types. In fibroblasts, vimentin filaments connect the nucleus to the plasma membrane and contribute to the formation of vimentin-associated matrix adhesions that are dynamically turned over in migrating cells (Ivaska et al., 2007) . Notably, vimentin null cells display reduced mechanical stability and motility in vitro (Eckes et al., 1998) and vimentin null mice show an impaired ability to heal wounds in vivo (Eckes et al., 2000) . Vimentin is also critical for the recycling of endocytosed cell adhesion receptors, integrins, to the plasma membrane and disruption of vimentin function results in impaired migration (Ivaska et al., 2005) . However, the mechanism(s) underlying the functional contribution of vimentin to epithelial cell migration remain unclear.
Many aggressive breast cancer cell lines express vimentin (Neve et al., 2006) . Moreover, overexpression of vimentin in a vimentin-negative, non-invasive MCF7 breast cancer cell line increases integrin traffic, migration and invasiveness (Hendrix et al., 1997; Ivaska et al., 2005) . Furthermore, several studies have reported overexpression of vimentin in breast cancer (reviewed in Kokkinos et al., 2007) . In particular, vimentin expression has been identified as a marker of basal-like breast cancer cells that may represent the clinical 'triple-negative' (ER, PR and HER2-negative) tumor-type associated with a poor prognosis (Neve et al., 2006) .
The phenotypic changes involved in EMT are a result of complex genetic changes. These are to some extent mediated by specific transcription factors capable of modulating the expression of E-cadherin and a large number of other EMT-associated genes in vitro. Expression of some of these transcription factors, such as Slug and Snail, has also been associated with a poor prognosis in a variety of human cancers (reviewed in Peinado et al., 2007) . Vimentin is a widely recognized marker of the EMT-like phenotype. However, it is not known whether vimentin functionally contributes to the gene expression pattern responsible for EMT phenotype or whether vimentin expression is merely a result of EMT.
To study the biological and functional role of vimentin in maintenance of the mesenchymal phenotype of malignant mammary epithelial cells, we induced EMT in the non-transformed MCF10A cells with Slug or oncogenic H-Ras-V12G and found that the increased migration of these cells was vimentin-dependent. We also analyzed vimentin-dependent changes in gene expression. Interestingly, silencing of vimentin resulted in downregulation of genes (AXL tyrosine kinase Axl, ITGB4 integrin b4 and PLAU plasminogen activator, urokinase). These genes have earlier been linked with breast cancer invasion and the basal-like phenotype (Neve et al., 2006; Schuetz et al., 2006; Lu et al., 2008a) . Moreover, knocking down vimentin induced expression of genes abundant in normal mammary epithelium (RAB25, small GTPase Rab25 and EHF, Ese3 transcription factor) (Galang et al., 2004; Cheng et al., 2006) . We studied further the interplay between vimentin, EMT induction and the receptor tyrosine kinase Axl, which is associated with a wide variety of malignancies (Linger et al., 2008) . Our results show vimentin-dependent regulation of Axl as an important mechanism underlying EMT-induced cell migration in breast cancer cells.
Results

Vimentin expression is dynamically induced in migrating cells
It has been proposed that EMT may be transient and reversible in human tumors (Thiery, 2002) . To investigate this in vitro, we studied the dynamics of vimentin expression in two different breast cancer cell lines. MCF10A cells are immortal, non-transformed breast epithelial cells that interestingly share characteristics with breast cancer cell lines of Basal B-like subtype (Neve et al., 2006) , whereas MDA-MB-231 represents a transformed, fibroblastic, highly metastatic basal-like breast cancer cell line.
We found that in comparison with confluent MCF10A cells, the cells located at the edge of a scratch-wound displayed upregulation of vimentin ( Figure 1a ) and actin stress fibers and a loss of E-cadherin (Supplementary Figure S1 ), in line with a previous report of low cell density-induced EMT in MCF10A cells (Sarrio et al., 2008) . Induction of vimentin was transient, as the expression returned to basal levels when the cells regained confluency (not shown).
When comparing with MCF10A cells, the MDA-MB-231 cells expressed more vimentin (Figure 1a) . Nevertheless, vimentin was further upregulated in the MDA-MB-231 cells located at the wound edge ( Figure 1a) . In a total cell lysate, the induction in vimentin was not detectable in MDA-MB-231 cells due to high basal levels of vimentin and the limited number of cells present at wound edges. MDA-MB-231 cells migrated significantly more than MFC10A cells in the scratch-wound assay (Figure 1b) . This was not due to differences in proliferation between the cell lines (Supplementary Figure S2a) .
These data show that vimentin expression is inducible in migrating cells, and that the amount of vimentin correlates positively with the migratory capacity of the breast cancer cells. Targeting vimentin with a pool of four siRNA oligos resulted in efficient silencing in MCF10A and MDA-MB-231 cells (Figure 1c ). Vimentin knock-down resulted in a significant inhibition of cell migration (but not proliferation; Supplementary Figure  S2b ) when compared with scrambled siRNA-transfected control cells in both cell lines (Figures 1d and e) . These data thus show that vimentin functionally contributes to the migration of these cells.
Wounding and expression of Slug or H-Ras induce EMT in MCF10A cells Several transcription factors have been shown to be involved in EMT. These include the transcription factor and E-cadherin repressor Slug (Nieto, 2002) . In addition, expression of oncogenic H-Ras-V12 is known to induce EMT in several cell types (Thiery, 2002) . As we had observed that MCF10A cells show reversible induction of vimentin in response to scratch wounding, we wanted to investigate the relationship between vimentin upregulation and known inducers of EMT in these cells. We observed that ectopic expression of H-Ras-V12G or Slug in MCF10A cells resulted in downregulation of E-cadherin and b-catenin (Figures 2a  and b ) and upregulation of vimentin (Figures 2a and b) . Interestingly, EMT induction with ectopic expression of known EMT inducers in MCF10A cells shares characteristics with the observed wounding-induced EMT as we detected induction of endogenous Slug at the wound edge in MCF10A cells (Figure 2c ).
Vimentin is necessary for Slug-and Ras-induced migration and upregulation of Axl Next, we tested the functional role of vimentin in EMTinduced MCF10A cells. Expression of Slug resulted in markedly elongated morphology of MCF10A cells (Figure 2d ). This was dependent on vimentin, as silencing of vimentin resulted in significantly rounder Vimentin induces migration via Axl K Vuoriluoto et al and increasingly spread cells (Figure 2d ). Cells, which have undergone EMT are more migratory. Time-lapse analysis of Slug, H-Ras-V12G or GFP-expressing MCF10A cells revealed that indeed Slug and H-Ras-V12G expression results in significantly induced motility (Figures 2e and f) . Importantly, silencing of vimentin resulted in very significant inhibition of migration also in the Slug and H-Ras-V12G-expressing cells (Figures 2e  and g ). Taken together, these data show that vimentin has an important function in induction of EMT-related migration downstream of transcription factor Slug or oncogenic H-ras.
Vimentin regulates Axl expression
To study the molecular basis for the influence of vimentin on EMT, the expression of vimentin was downregulated with siRNA in MCF10A cells, as these cells display very dynamic regulation of vimentin in response to cell density, and cDNA microarrays were performed. We found that 85 genes were significantly upregulated and 35 downregulated (Gene Expression Omnibus accession GSE17802). The heatmap in Figure 3a shows the expression of 11 differentially regulated genes normalized to median of the control, scrambled siRNA sample (siScr).
Quantitative PCR analyses verified that vimentin was efficiently inhibited by the siRNA (Figure 3b ). Moreover, downregulation of the expression of three other genes (AXL, PLAU and ITGB4), which have been linked to breast cancer cell migration and invasiveness (Neve et al., 2006; Schuetz et al., 2006; Lu et al., 2008a) , in the vimentin-silenced cells was readily detectable by real-time PCR (Figure 3b ). 
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Vimentin and Axl expression correlate positively in clinical cancer samples Next, we wanted to study whether the expression of vimentin and the differentially regulated genes, identified using microarray, correlate also in patients and other cell lines. To this end, we integrated data from multiple gene profiling studies of breast cancer clinical samples (733 patients), normal breast tissues (179 persons) and breast cancer cell lines (92 lines), and analyzed the expression of vimentin, AXL, PLAU, RAB25, ITGB4, KRT6B (keratin 6B) and KLK5 (Richardson et al., 2006; Loi et al., 2007; Turashvili et al., 2007; Lu et al., 2008b; Marty et al., 2008; Bos et al., 2009; Burga et al., 2009; Chen et al., 2010) (Figure 3c ). We observed that the expression of vimentin correlated positively with AXL, PLAU and ITGB4 (albeit more weakly) both in the clinical cancer material and the cancer cell lines. Interestingly, the positive correlation was also found in normal tissue samples for vimentin, AXL and PLAU (but not ITGB4), suggesting that vimentin can be a key regulator of these genes also under non-pathological conditions. A strong negative correlation between vimentin and Rab25 was evident in all the samples, showing that co-expression of these two genes is rare in breast tissue both in vitro and in vivo (Figure 3c ). Finally, expression of KLK5 and KRT6B was inversely proportional to vimentin in normal tissue both in vitro and in vivo, whereas there was a positive correlation between vimentin and KRT6B in the cancer samples. Taken together, these data show that vimentin expression correlates either negatively or positively with the genes identified in the silencing experiment also in a qRT-PCR analysis of mRNA levels in MCF10A after silencing of vimentin relative to scrambled siRNA-transfected cells. The data were normalized using GAPDH as an endogenous control. The results are mean ± s.e.m. of three experiments with two to three parallels. (c) Co-expression analysis of AXL, VIM and several other genes among 733 breast carcinoma and 179 normal samples, and 92 breast cancer cell lines. A strong positive correlation value is shown as a dark red color, whereas a strong negative correlation value is shown as a dark blue color (*Po0.045, **Po0.009, ***Po2 Â 10 À5 ).
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Vimentin and Axl are co-upregulated in migratory cells at wound edges Axl is a receptor tyrosine kinase implicated in haptotaxis in certain models (Holland et al., 2005) . Therefore, we wanted to study in detail the possible mechanistic connection between Axl and vimentin expression. In line with a more migratory phenotype and higher vimentin expression, both the mRNA and protein expression of Axl were significantly higher in MDA-MB-231 cells than MCF10A cells (Figures 4a and b) . Furthermore, expression of Slug and H-Ras-V12G significantly induced Axl levels in MCF10A cells (Figures 4c and d) , which would be in line with the induction of vimentin in these cells (Figures 2a and b) . This suggests that vimentin and Axl could both contribute to the increased migration of breast cancer cells. We found that vimentin and Axl did not colocalize even in the highly migratory MDA-MB-231 cells. However, Axl was clearly localized to the lamellipodia of cells polarizing toward the scratch wound (Figure 4e) , indicative of a possible role in cell migration. Moreover, both vimentin and Axl were upregulated at the cells immediately adjacent to wound Vimentin induces migration via Axl K Vuoriluoto et al edge compared with the following cells (Figure 4e ). Axl was induced and E-cadherin downregulated also in MCF10A cells migrating at the wound edge (resembling Slug-expressing cells) ( Figure 4f ). Next, we tested whether vimentin expression influenced Axl protein levels. Vimentin-silenced MDA-MB-231 cells exhibited 56% reduced total Axl protein levels. In contrast, knocking down Axl had no effect on vimentin expression (Figure 5a ). Three individual siRNAs against vimentin and two against Axl gave similar results (Supplementary Figure S3a) , which strongly argue for the specificity of the effects. These data thus show that vimentin induces Axl expression in breast cancer cells. Furthermore, silencing of vimentin in GFP, Slug and H-Ras-V12G-transfected MCF10A cells was sufficient to decrease Axl levels significantly (Figures 5b and c) . Thus, vimentin expression seems to be necessary for Slug-or Ras-induced Axl induction.
Axl expression increases migration
Silencing of vimentin or Axl with several siRNAs in MDA-MB-231 cells inhibited migration significantly compared with control cells (siScr) (Figure 6a ; Supplementary Figure S3b ). Similar results were obtained also when vimentin or Axl were silenced in MCF10A cells (Figure 6b ) and H-Ras-V12G-expressing MCF10A cells (Figure 6c ). These data show that vimentin and Axl are both important regulators of migration of breast cancer cells.
We then studied whether the ability of Axl to drive cell migration is dependent on vimentin expression. The SW13 cell line derived from human adrenal adenocarcinoma has two subtypes either containing vimentin intermediate filaments or not (SW13vim þ or SW13vimÀ, respectively; Figure 7a ) (Hedberg and Chen, 1986) . Neither subtype expressed detectable levels of endogenous Axl (Figure 7a ). These cells were Vimentin and Axl regulate cell migration. Representative quantifications of two 6 h scratch-wound migration experiments with (a) MDA-MB-231 (mean ± s.e.m., four parallels; **Po0.001) and (b) MCF10A (mean ± s.e.m., seven parallels; **P ¼ 0.006, ***P ¼ 0.0004) cells silenced with indicated siRNAs. (c) Migration of siRNA-silenced MCF10ARas cells was followed by time-lapse imaging for 17 h at 12-min intervals (mean±s.e.m., n ¼ 43-47; ***Po2 Â 10 À10 ). Figure S4) . In the control-transfected samples, SW13vim þ cell line migrated significantly (P ¼ 0.02) better than cells not expressing vimentin (SW13vimÀ). Axl overexpression induced migration in both subtypes, albeit more efficiently in SW13vimÀ cells (199 ± 4%, P ¼ 0.002) compared with SW13vim þ cells (130 ± 3%, P ¼ 0.009) (Figure 7b ). These data thus show that vimentin controls migration in breast cancer cells via regulating endogenous Axl, and that ectopic Axl expression drives migration independently of vimentin expression.
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Vimentin induces migration via regulation of Axl levels
It has remained unclear how vimentin affects cell migration. The novel link between vimentin and Axl expression led us to investigate whether induction of Axl is required for vimentin-dependent migration. We generated MDA-MB-231 cells with stable shRNAmediated silencing of Axl (231shAxl) that exhibit significantly reduced Axl levels both on the cell surface and as total cellular Axl protein ( Figure 8a ). As expected, Axl-silenced cells migrated less than control transfected cells (Figure 8b ). The differences in cell migration were not due to altered cell adhesion properties, as both cell lines adhered equally to extracellular matrices collagen and fibronectin (Supplementary Figure S5) . Interestingly, silencing of vimentin was unable to further reduce migration of 231shAxl cells with downregulated Axl expression, whereas migration of control 231shLuc cells was inhibited by 49±6% ( Figure 8b ). This suggests that vimentin supports migration in these cells, at least in part, via control of Axl expression. As silencing of vimentin downregulated endogenous Axl mRNA levels in MCF10A cells (Figures 3a and b) , we assessed whether Axl expressed by a different exogenous promoter is influenced by vimentin levels. We generated a stable MDA-MB-231 cell line with CMV IE promoter-driven Axl expression (231Axl). However, likely due to high endogenous Axl expression, only a relatively modest (21%) upregulation of Axl was achieved (Figure 8c) . Nevertheless, the upregulation of Axl induced migration of these cells further (P ¼ 3 Â 10 À6 ) (Figure 8d ). This was dependent on Axl kinase activity as stable MDA-MB-231 cells expressing kinase-dead Axl (KDAxl) migrated identically to control cells (Supplementary Figure S6) . Simultaneous silencing of vimentin inhibited migration of both Axl overexpressing and control cells, as would be expected due to concomitant reduction in endogenous Axl. However, in cells expressing exogenous Axl, vimentin silencing inhibited migration only 49±5% compared with 65±5% inhibition of migration in control cells (based on Figure 8d ). These data show that an important mechanism underlying vimentin-induced migration of MDA-MB-231 breast cancer cells is the induction of Axl expression.
Both vimentin and Axl contribute to migration on three-dimensional matrix and lung extravasation Cell migration can be dramatically different when cells are cultured in a three-dimensional matrix (Cukierman et al., 2001; White et al., 2007) . Thus, we investigated migration of siRNA-transfected 231shLuc and 231shAxl cells on a cell-derived matrix using time-lapse imaging and cell tracking. Also on the three-dimensional matrix, silencing of vimentin inhibits migration (Figures  8e and f) . Furthermore, also under these conditions, silencing of vimentin had less effect on migration in shAxl cells compared with shLuc cells. Next, we investigated the ability of tail vein-injected shAxl and shLuc MDA-MB-231 cells to extravasate from the blood stream to lungs in mice. Importantly, Axl-silenced cells (red) extravasated from the lung vasculature significantly less than shLuc cells (green); 48 h postinjection, only 52% of shAxl cells retained in the lungs had extravasated (not stained during 5 min in vivo perfusion with anti-human HLA antibody; 647-negative cells) compared with 87% extravasation of the shLuc cells (Figure 8g ). This was not due to differences in proliferation, as proliferation rates of the cell lines were equal (Supplementary Figure S7) . These data thus suggest that vimentin-dependent Axl induction is important for breast cancer cell migration in three dimensions and that Axl contributes to extravasation from the blood stream in vivo. , ***P ¼ 5 Â 10 À7 ). (e, f) The shLuc or shAxl MDA-MB-231 cells were transfected with siScr or siVim, plated on 3T3 fibroblast-derived matrix, and allowed to spread for 3 h. Migration was time-lapse imaged at 10-min intervals. The 16-h migration tracks of 10 representative cells in each condition are visualized in (e) and quantitation of distance to start is shown in the chart (f). The results are a representative of two similar experiments (mean±s.e.m., n ¼ 52-75; *P ¼ 0.012, **P ¼ 0.008, ***P ¼ 3 Â 10
À5
; NS = not significant). (g) shLuc (green) or shAxl (red) MDA-MB-231 cells were pre-labeled with fluorescent cell trackers and intravenously injected together (5 Â 10 5 cells each) into mice. After 48 h, cells remaining in circulation were stained with mouse anti-human HLA-antibody for 5 min. Cells from one lung per mouse were isolated, stained with Alexa-647 secondary antibody and quantified based on fluorescence, and the other lung was processed to lung sections and counterstained with dapi. (Section from one mouse is shown as a representative. Scale bar, 50 mm.) The results are expressed as mean ( ± s.e.m.) percentage of specified cells from all cells isolated and scored per mouse (n ¼ 10; *P ¼ 0.011, **P ¼ 0.008). Western blotting is of the cells injected in mice.
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Discussion
Here, we have investigated the functional role of vimentin in basal-like breast cancer cell lines (Neve et al., 2006) . Our microarray analyses revealed that vimentin regulates expression of several genes associated with EMT and the basal-like phenotype. Furthermore, analysis of clinical material in a large cohort of breast cancer patients and normal tissue shows correlation between expression of vimentin and these genes in vivo.
Our data show a previously unknown and important link between vimentin and the expression of Axl and suggest that Axl is an important proximal mediator of vimentin-induced effects on cell motility. We show that silencing of vimentin results in downregulation of Axl on mRNA and protein levels and subsequent inhibition of cell motility. Vimentin-mediated effects on cell migration depend at least in part on the expression of Axl, whereas overexpressed Axl is able to drive cell motility even in the absence of vimentin. Importantly, we show that Axl contributes functionally to extravasation of breast cancer cells from the blood stream in mice. We also show that Slug-and Ras-induced EMT changes (cell migration, morphology and induction of Axl) are dependent on the upregulation of vimentin. These findings would be in line with a model (Figure 9 ) in which vimentin appears as an important signaling integrator in EMT.
Although vimentin is a widely used marker of the mesenchymal phenotype, data detailing any functional role for it in EMT are relatively scant. Several studies have addressed the correlation between vimentin expression and cell migration. Inhibition of vimentin filament integrity was very recently shown to cause mesenchymal cells to adopt epithelial shape and to inhibit migration (Mendez et al., 2010) . Expression profiling of breast cancer has shown that vimentinexpressing cancers are mesenchymal or Basal B type (Neve et al., 2006; Sarrio et al., 2008; Sotiriou and Pusztai, 2009 ). These tumors are undifferentiated, fibroblastic and likely to form distant metastases to tissues like lung and brain, and thus show unfavorable prognosis (Rodriguez-Pinilla et al., 2006; Sarrio et al., 2008) . Therefore, it is highly relevant to study how vimentin could functionally mediate altered cell migration.
Axl is a receptor tyrosine kinase that is stimulated by the secreted protein Gas6 (growth arrest specific 6) (Stitt et al., 1995; Varnum et al., 1995) . Expression of Axl with its ligand Gas6 has been reported in many cancer types (Linger et al., 2008) . Gas6-activated Axl signaling marshalls important downstream regulators of cell motility such as Rac and Akt (Allen et al., 2002; Hasanbasic et al., 2004) and regulates haptotaxis toward vitronectin in endothelial cells (Holland et al., 2005) . Recent studies support a role for Axl as a regulator of glioma, breast, lung and pancreatic tumor cell migration (Shieh et al., 2005; Vajkoczy et al., 2006; Koorstra et al., 2009 ) and very recently Axl was identified as an important regulator of breast cancer metastasis and survival of patients (Vajkoczy et al., 2006; Gjerdrum et al., 2010) . We found that vimentin regulates Axl expression in breast cancer cell lines. Interestingly, a recent gene expression profiling study on cancer cell lines showed that 14 vimentin-positive basal-like cell lines were also more likely to express Axl compared with vimentin-negative cells (Neve et al., 2006) . This is in line with our gene expression profiling data, which shows that vimentin and Axl expression correlate also in vivo. Importantly, our data indicate that Axl and vimentin expression profiles correlate in a large number of cell lines and in breast tissue of 912 patient samples (both normal and cancer). This suggests that vimentinmediated regulation of Axl is relevant in vivo and is not restricted to basal-like breast cancer cells. At present, we do not know the exact mechanisms how vimentin regulates Axl transcription. However, increasing evidence points to a role for vimentin as a signaling hub (Ivaska et al., 2007; Kumar et al., 2007; Phua et al., 2009) and thus loss of vimentin may abolish specific signaling pathways.
In conclusion, our results show that vimentin functions as a regulator of Axl and that vimentin enhances cell migration by inducing Axl. This is consistent with a model in which Axl is a novel downstream effector of EMT and vimentin in tumor cells. Hence, Axl represents a novel therapeutic target for vimentin-positive mesenchymal cancer cells. Receptor tyrosine kinases are a well-established cancer therapeutic class and Vimentin induces migration via Axl K Vuoriluoto et al small-molecule inhibitors of Axl tyrosine kinase activity have been reported (Zhang et al., 2008) . As we and others have shown that kinase-dead Axl is unable to induce migration (Supplementary Figure S6 ; Holland et al., 2005) , we hypothesize that disruption of Axl signaling using a small-molecule inhibitor may inhibit formation of distant metastases in Basal B-like breast tumors.
Materials and methods
Antibodies and stainings
The following antibodies were used-anti-vimentin #SC-6260, anti-Axl: H-124 #SC-20741 (Santa Cruz Biotechnology, San Diego, CA, USA) and MAB154 (R&D Systems, Minneapolis, MN, USA), anti-Slug L40Cb (Cell Signalling Technology, Danvers, MA, USA), anti-E-cadherin ab1416 (Abcam, Cambridge, MA, USA), anti-N-cadherin ab18203 (Abcam), anti-b-catenin ab32572 (Abcam), anti-Hsc70 SPA-815F (Stressgen Bioreagents, Victoria, BC, Canada), anti-b-actin ab8226 (Abcam), anti-a-tubulin 12g10 (Hybridoma Bank, University of Iowa) and anti-H-Ras MCA2884 (AbD Serotec, Kidlington, UK). Flow cytometry (Gjerdrum et al., 2010) , western blot (Tuomi et al., 2009) and immunofluorescence (Vuoriluoto et al., 2008) were performed as described earlier.
Plasmids and transfections
Axl construct used for stable expression was of a COOHterminally myc-tagged Axl cDNA (480-3140) expressed in pIRES-GFP (Holland et al., 2005) . I.M.A.G.E. Consortium cDNA Clone encoding Slug (ID 3911047) from Open Biosystems (Huntsville, AL, USA) was also expressed in pIRES-GFP. pBabe-puro H-Ras-V12G vector was distributed by Addgene and was originally donated by B Weinberg. shRNAs were expressed from a modified human U6 promoter in the LTR of the retroviral L087 or RRI-Green/L071 (Genbank: EU424172) used to transform MDA-MB-231 cells via retroviral infection. H-Ras-V12G was also introduced to the cells via retroviral infection followed with puromycin selection. Vimentin siRNAs (SMARTpool M-003551-01-005: Dharmacon, Chicago, IL, USA; #SI00302190, #SI002655198: Qiagen, Valencia, CA, USA), Axl siRNAs (#SC-29769, #SC-44285; Santa Cruz Biotechnology) or scrambled (AllStars Negative Control; Qiagen) were transfected using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instructions. shRNAs used are as followsshAxl2: GACATCCTCTTTCTCCTGCGAAGCCCATctggtc ATGGGCTTCGCAGGAGAAAGAGGATGC, shLuc: GA TTATGTCCGGTTATGTAAACAATCCGGCTGGTCCCGG ATTGTTTACATAACCGGACATAATC.
Migration assays and microscopy
For live-cell imaging, cell-derived matrix was generated using NIH 3T3 fibroblasts as described previously (Cukierman et al., 2001; Caswell et al., 2007) . Before live-cell imaging, 231shLuc and 231shAxl cells were allowed to spread for 2 h on matrix coat, and MCF10AGFP, MCF10ASlug, and MCF10ARas were allowed to grow on plastic for 8-24 h. Images were analyzed with the NIH ImageJ. Circularity was measured with the ImageJ's Measure command that calculates object circularity using the formula circularity ¼ 4p(area/perimeter 2 ). Scratch-wound assays were performed as described (Pellinen et al., 2006) .
RNA isolation, microarrays and qRT-PCR
See Gene Expression Omnibus accession GSE17802. The expression of mRNA of the genes studied was determined by relative quantitation method using either GAPDH or ACTB as an endogenous control. The expression analysis of the cell lines and human samples (cancer, normal) was performed from published and Gene Expression Omnibus-submitted Affymetrix data as described in Kilpinen et al. (2008) .
Lung extravasation assay
Female athymic nude mice (Hsd:Athymic Nude-nu; Harlan Scandinavia, Allerod, Denmark), aged between 4 and 6 weeks, were used for the xenograft studies. All of the experimental procedures were approved by the local ethical committees. Mice were anesthetized with ketamine (Pfizer) and xylazine (Bayer). shAxl and shLuc MDA-MB-231 cells were stained with live cell dyes (shAxl red, CMTPX; shLuc green, CMFDA: Invitrogen) according to the manufacturer's instructions. Cells were harvested, suspended in 50 ml PBS (5 Â 10 5 each) and injected into lateral tail vein of mice (n ¼ 10); 48 h postinjection, the mice were injected with mouse anti-human HLA antibody (Hb116; Koskinen et al., 2004) 34 mg/ml for 5 min (to distinguish between human cells adhering to the vessel wall from those that have extravasated inside the tissue). Next, the pulmonary vasculature was perfused with PBS through the right ventricle (2 min) and blood was allowed to escape by a small incision in the left atrium. The animals were killed. Cells were harvested from one lung per animal with collagenase XI treatment for 1 h þ 37 1C, washed with PBS and stained with anti-mouse Alexa-647 antibody and analyzed based on fluorescence using ScanR automated microscope. The other lung was processed to sections and stained with dapi as described earlier (Chabottaux et al., 2009) .
Statistical analyses
Statistical analyses were performed using Student's t-test for two-tailed distribution with two-sample unequal variance, except in the integrated gene profiling studies, Spearman's correlation test was used.
